Current situation and perspective of COVID-19 mRNA vaccine

ABSTRACT

In December 2019, Wuhan, China, found SARS-CoV-2. It causes covid-19, a worldwide respiratory illness. Its global pandemic broke out unexpectedly, and the number of infections and deaths continued to rise dramatically, causing the collapse of medical systems and disease control organizations in many countries at the start of the outbreak. Vaccine research and development must be prioritized in order to control and reduce virus spread as soon as possible. The mRNA vaccine stands out among traditional vaccines due to its rapid research and development, ability to stimulate human dual immune responses and non-infectivity. Both humoral and cellular immunity can be stimulated by mRNA vaccines, which means that the produced T cells can help eliminate antigens in time, so their number does not increase in order to protect the original cells, and they can also create long-lived plasma cells and memory B cells to continue playing an immunological role for years. mRNA vaccines may not need repeated injections, unlike inactivated vaccinations, which may enhance efficiency. the first mRNA vaccinations that were made accessible to the general population when the US FDA approved its emergency use in December 2020. The generation of mRNA for the mRNA vaccination uses cell-free expression techniques and in vitro transcription-based systems. LNPs system, a nanoscale vesicle that can enclose mRNA in their cavity and imitates the lipid structure of the cell membrane, is the most often utilized delivery system in mRNA vaccines. The most common mRNA vaccine technique involves injecting a genetic component that tells the body to make a protein fragment of a specific pathogen, which the immune system recognizes and keeps mounting a robust response if it is subsequently exposed to that pathogen. © 2023 SPIE.